Close Menu

NEW YORK – A subset of tumors from a rare, metastasis-prone subtype of pancreatic cancer known as adenosquamous carcinoma may be susceptible to treatments that target FGFR and other pathways identified through genomic and chromatin profiling, according to findings from investigators at the Mayo Clinic and elsewhere.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
27
Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

May
26
Sponsored by
Lexogen

The emergence of cell clones that are resistant to targeted therapies poses a significant issue in the treatment of metastatic melanoma.